Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Phase II Reactions: Methylation Reactions

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Edinburgh Postnatal Depression Scale.

Occupational medicine (Oxford, England)·2026

Same author

Function-based reorganization of general hospital psychiatry in Japan: A perspective.

Journal of psychosomatic research·2026

Same author

Headache psychiatry: A structured narrative review and integrative framework.

PCN reports : psychiatry and clinical neurosciences·2026

Same author

Digital harassment and its mental health impact among healthcare professionals: A scoping review.

PCN reports : psychiatry and clinical neurosciences·2026

Same author

Diagnostic visibility and context-dependent referral patterns in consultation-liaison psychiatry: A ten-year retrospective study.

General hospital psychiatry·2026

Same author

Hypnotic-associated falls across the diurnal cycle: Pharmacokinetic signal or delirium rhythm?

Psychiatry and clinical neurosciences·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.

Kyohei Otani¹, Hiroshi Ujike, Ayumu Sakai

¹Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho 2-5-1, Okayama 700-8558, Japan.

Neuroscience Letters

|February 19, 2008

Summary

This summary is machine-generated.

Reduced activity of the CYP2D6 enzyme may protect against methamphetamine dependence. This study found fewer intermediate metabolizers in methamphetamine-dependent individuals, suggesting a negative risk factor.

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

Pharmacogenetics
Neuroscience
Addiction Research

Background:

Methamphetamine (METH) metabolism involves the CYP2D6 enzyme.
Functional variants in CYP2D6 may influence susceptibility to METH dependence.

Purpose of the Study:

To investigate the association between CYP2D6 gene variants and methamphetamine dependence in a Japanese population.
To determine if CYP2D6 metabolic activity impacts the risk of developing METH dependence.

Main Methods:

Genotyping of CYP2D6 alleles (*1, *4, *5, *10, *14) in 202 METH-dependent patients and 337 controls.
Classification of subjects into CYP2D6 metabolic phenotypes (extensive, intermediate, poor metabolizers).

Main Results:

A significant association was found between CYP2D6 gene variants and METH dependence (p=0.0299).
Hypofunction alleles (*10, *14) were less frequent in METH-dependent patients.
Intermediate metabolizers were significantly fewer in the METH-dependent group (p=0.0212; OR=0.62).

Conclusions:

Reduced CYP2D6 metabolic activity is associated with a lower risk of developing methamphetamine dependence.
CYP2D6 genotype and phenotype are potential factors influencing susceptibility to METH-induced dependence.